Andrew Henderson

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Kaja Abbas et autres

BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital …

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima Abbas, Jonathan R. Abbas et autres

BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY …

Pearls and Pitfalls in the Management of Vascular Anomalies

Omar Sanon, Andrew Henderson, Robert J. Rosen

Recent advancements in endovascular techniques have transformed the management of vascular malformations, shifting away from traditional surgical resections to less invasive methods like embolization and sclerotherapy. Vascular malformations are congenital anomalies resulting from embryonic angiogenesis failures, often misdiagnosed but manageable through a …

us (code pays fourni par la source)

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, Charles E. Alpers et autres

us, gb, nl, au, kr, de, it, be, pl, br, es, hk, cz, ar (code pays fourni par la source)

Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol

Dana de Kretser, Jocelyn Mora, Max Bloomfield, Anita J Campbell et autres

BACKGROUND: Staphylococcus aureus bloodstream infection (bacteremia) is traditionally treated with at least 2 weeks of intravenous (IV) antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia (SAB) with …

gb, au, nz, ca, nl, sg, us, il, kr, fr (code pays fourni par la source)

Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions

Minggui Wang, Lizhao Ge, Liang Chen, Lauren Komarow et autres

BACKGROUND: Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the most problematic antimicrobial-resistant bacteria. We sought to elucidate the international epidemiology and clinical impact of CRAb. METHODS: In a prospective observational cohort study, 842 hospitalized patients with a clinical CRAb culture were enrolled …

cn, us, co, sa, lb, ar, sg, cl, ni, au, jp (code pays fourni par la source)

In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial

Adam G. Stewart, Michelle J. Bauer, Dominika Butkiewicz, Alexandra O. Hinton et autres

au, sg (code pays fourni par la source)

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers, Jonathan Barratt et autres

nl, au, us, gb, br, ar (code pays fourni par la source)

Determining thein vitrosusceptibility of tebipenem, an oral carbapenem, against third-generation cephalosporin-resistantEscherichia coliandKlebsiella pneumoniaeisolated from bloodstream infections

Ama Ranasinghe, Andrew Henderson, Kyra Cottrell, Cindy S. E. Tan et autres

Abstract Background Antimicrobials for bloodstream infections due to ESBL- and AmpC-producing Escherichia coli and Klebsiella pneumoniae are significantly limited due to widespread antimicrobial resistance. Tebipenem, an oral carbapenem, exhibits stability against these resistance mechanisms and may prove an attractive alternative. Methods The …

au (code pays fourni par la source)

TheStaphylococcus aureusNetwork Adaptive Platform Trial Protocol: New Tools for an Old Foe

Steven Y. C. Tong, Jocelyn Mora, Asha C Bowen, Matthew P. Cheng et autres

Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%-30%. Despite this, <3000 people have been randomized into clinical trials of treatments for SAB infection. The limited evidence base partly results from clinical trials …

au, ca, gb, us, sg, nz, il (code pays fourni par la source)

Epidemiology of ascites fluid infections in patients with cirrhosis in Queensland, Australia from 2008 to 2017

Isanka U. Ratnasekera, Amy Johnson, Elizabeth E. Powell, Andrew Henderson et autres

ABSTRACT: Spontaneous bacterial peritonitis (SBP), a common infection in patients with cirrhosis and ascites, is associated with high morbidity and mortality. The aim of this study was to investigate changes in the epidemiology of ascites fluid infections over time in an Australian …

au (code pays fourni par la source)

Clinical prediction scores and the utility of time to blood culture positivity in stratifying the risk of infective endocarditis in Staphylococcus aureus bacteraemia

Peter Simos, David J. Holland, Adam G. Stewart, Burcu Isler et autres

BACKGROUND: Infective endocarditis (IE) complicates up to a quarter of Staphylococcus aureus bacteraemia (SAB) cases. Risk scores predict IE complicating SAB but have undergone limited external validation, especially in community-acquired infections and those who use IV drugs. Addition of the time to …

au (code pays fourni par la source)